ASCO Gastrointestinal Cancers Symposium

Bild/Picture ®Thomas Ferber/Oncoletter

  • Rapid Abstract Session A: Cancers of the Esophagus and Stomach
  • Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
  • Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus

Rapid Abstract Session A: Cancers of the Esophagus and Stomach

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, et al.

In advanced HER2-positive adenocarcinoma of the gastric or gastroesophageal junction, trastuzumab deruxtecan (T-DXd) continues to have an overall survival benefit and demonstrates a clinically relevant improvement in ORR over standard chemotherapy. The safety profile is good to deal with. More info: NCT03329690.

 

Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial.

Zev A. Wainberg, Kohei Shitara, Eric Van Cutsem, et al.

After more than two years of follow-up of first-line therapy, the efficacy and safety results of pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy in patients with gastric or gastroesophageal junction adenocarcinoma included in KEYNOTE-062 did not differ from the final analysis data. Clinical Trial Information: NCT02494583.

 

Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study.

Thierry Andre, David Tougeron, Guillaume Piessen, et al.

Nivolumab plus ipilimumab neoadjuvant is possible: it leads to a high pCR rate in patients with MSI/dMMR-resectable OGA. More info: NCT04006262.

 

Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).

Yu Sunakawa, Ryo Matoba, Toshizo Takayama, et al.

Upon treatment with nivolumab, finding the genus Arthrobacter and determining the fatty acid pathway in the gut microbiome can predict skin toxicities in advanced gastric cancer, and various SNPs may be markers for skin toxicity and diarrhea. More information: UMIN000030850.

 

A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer.

Jiafu Ji, Lin Shen, Xiangyu Gao et al.

In treatment-naïve advanced adenocarcinoma of the stomach and gastro-jejunal junction (G/GEJ), AK104 combined with mXELOX/XELOX proved to be a promising and potentially new first-line treatment option. Security was manageable. More info: NCT03852251.

 

More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI 

To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.

Rapid Abstract Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.

Tanios S. Bekaii-Saab, Alexander I. Spira, Rona Yaeger, et al.

Well-tolerated monotherapy with adagrasib results in encouraging clinical activity in previously treated pancreatic ductal adenocarcinoma and other GI tumors harboring a KRASG12C mutation. More info: NCT03785249.

 

Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, et al.

The study results show that both etoposide plus cisplatin and irinotecan plus cisplatin remain equivalent as standard first-line chemotherapy. More information: UMIN000014795

 

Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT).

Masafumi Ikeda, Kohei Nakachi, Masaru Konishi, et al.

In contrast to surgery alone, significantly longer survival can be achieved with adjuvant S-1 therapy. This therapy is thus becoming the treatment standard for resected biliary tract cancer. Clinical trial information: UMIN000011688.

 

Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Shukui Qin, Zhendong Chen, Weijia Fang, et al.

Consistent with the results from KEYNOTE-224 and KEYNOTE-240, the present study results add to the body of evidence that the use of pembrolizumab as second-line therapy for advanced HCC is warranted. More info: NCT03062358

 

Randomized phase III study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: The CISPD3 trial.

Qihan Fu, Yiwen Chen, Dabing Huang, et al.

Combined PD-1 blockade may extend the benefit of chemotherapy in PDAC. The study authors reached this conclusion based on their observation that the addition of sintilimab to mFFX significantly improved ORR in patients with advanced PDAC. However, superior overall and progression-free survival was not observed. More info: NCT03977272.

 

More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI 

To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.

Rapid Abstract Session C: Cancers of the Colon, Rectum, and Anus

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer.

Van K. Morris, Christine Megerdichian Parseghian, Michelle Escano, et al.

The proposed treatment has met its predefined efficacy endpoint. This suggests a role for immunotherapy as a novel combination approach for this specific subpopulation of metastatic CRC in MSS. More info: NCT04017650.

 

One-year duration of nivolumab plus ipilimumab in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up of the GERCOR NIPICOL phase II study.

Romain Cohen, Aurelia Meurisse, Thomas Pudlarz, et al.

Follow-up also continues to demonstrate sustained activity in patients with chemoresistant MSI/dMMR-mCRC. Interesting: Re-administration of nivolumab appears to result in additional antitumor activity in patients who develop late resistance after immunotherapy discontinuation. More info: NCT03350126

 

Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): Short-term outcomes of a multicenter randomized controlled trial.

Jianmin Xu, Weitang Yuan, Taiyuan Li, et al.

Robotic surgery for middle and lower rectal cancer is superior to conventional laparoscopic surgery: it significantly reduced surgical injury, improved oncological radicality, and promoted postoperative recovery. More info: NCT02817126.

 

Phase I/II study of regorafenib (rego) and pembrolizumab (pembro) in refractory microsatellite stable colorectal cancer (MSSCRC).

Afsaneh Barzi, Nilofer Saba Azad, Yan Yang, et al.

The study did not meet its primary endpoint, although study authors said the median OS was "provocative."More info: NCT03657641.

 

PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer.

Melissa Amy Lumish, Jenna L. Cohen, Zsofia Kinga Stadler, et al.

Dostarlimab neoadjuvant is effective and well-tolerated, allowing patients with locally advanced rectal adenocarcinoma with dMMR to avoid chemoradiation and surgery. The study authors thus point to a potential new paradigm for the treatment of dMMR locally advanced rectal cancer. More info: NCT04165772.

 

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).

Takayuki Yoshino, Maria Di Bartolomeo, Kanwal Pratap Singh Raghav et al.

With longer-term follow-up Trastuzumab deruxtecan (T-DXd; DS-8201) showed promising activity and durability. The safety profile did not differ from previous results; The study authors note that interstitial lung disease remains an important identified risk that needs to be carefully monitored so that intervention can be made if necessary. More info: NCT03384940.

 

More info about General Sessions, Poster Sessions, Trials in Progress Poster Sessions: please refer to the program guide from ASCO-GI

To attend the presentations, slides etc. you need a paid registration from ASCO. Please refer to ASCO GI’s website.

Dienstleistungen

  • Livecasts
  • Kongress-Berichte
  • Journal-Review
  • Interviews
  • Videos

Impressum

Oncoletter wird über nicht öffentlich zugängliche Werbung für Medizinalpersonen finanziert. Oncoletter finanziert sich zudem mit von Gesundheitsorganisationen (z.B. Universitätsspital, Swiss Academy of Multidisciplinary Oncology SAMO), Stiftungen (z.B. SONK St.Gallen Oncology Conferences) beauftragten Aufnahmen ganzer Kongresse oder Symposien. Weiter erhält Oncoletter nicht an inhaltliche Bedingungen geknüpfte Unterstützung von Firmen zur Berichterstattung. Seit der Inbetriebnahme von Oncoletter haben folgende Firmen die Webseite vorübergehend/permanent und in wechselnden Zusammensetzungen (jährlich 4-6) unterstützt: Amgen, BMS, Celgene, GSK, Janssen-Cilag, Lilly, Merck, Mundipharma, Novartis, Pfizer, Roche, Servier.
Die Inhalte der Website von Oncoletter sind strikt redaktionell und widerspiegeln die Meinungen und Ansichten der Autoren. Bei ausnahmsweise bezahlten Beiträgen oder Interviews (ausschliesslich on-label) wird der Sponsor im Text oder Abspann aufgeführt.

Kontakt

Oncoletter
DR. MED. THOMAS FERBER
CH-8200 SCHAFFHAUSEN

info[@]oncoletter.ch

Copyright 2024. All Rights Reserved.
You are using an outdated browser. The website may not be displayed correctly. Close